An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Trial Profile

An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Raxatrigine (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Sponsors Biogen; Convergence Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2017 Planned End Date changed from 28 Feb 2019 to 22 Jul 2020.
    • 01 Dec 2017 Planned primary completion date changed from 28 Feb 2019 to 22 Jul 2020.
    • 28 Sep 2017 Planned End Date changed from 27 Dec 2018 to 28 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top